Maxion Therapeutics wins ‘Start-up of the Year’ at 2023 Cambridge Independent Science & Technology Awards
- Recognition of company’s technology, progress, and stellar team, including co-founders John McCafferty and Aneesh Karatt Vellatt
Cambridge, UK – Maxion Therapeutics is pleased to announce its ‘Start-up of the Year’ win at the 2023 Cambridge Independent Science & Technology Awards. It was selected by a panel of judges from a competitive shortlist of impressive Cambridge-based finalists. In their sixth year, the Awards are recognised as a celebration of the extraordinary talent in the region across a host of science and technology sectors.
Dr John McCafferty, CEO and co-founder of Maxion Therapeutics, said:
Daniel Zeichner, MP for Cambridge, who attended the Awards ceremony along with a small delegation from Maxion and other Awards finalists on 18 May, said that the Awards celebrate “the very best in science and technology in and around Cambridge.”
Maxion’s KnotBody technology combines the power of millions of years of cysteine-rich miniprotein (‘Knottin’) evolution with state-of-the-art phage and mammalian display technologies. It addresses key challenges in drug discovery for ion channels and GPCRs, which are critical cell surface proteins involved in a wide range of untreated or poorly-treated diseases, including autoimmune diseases (AID) and chronic pain.
Last month, Maxion announced it had been awarded a prestigious £2 million grant from Innovate UK to apply its propriety KnotBody® platform to develop antibodies to treat AID with high unmet clinical need. In February 2023, the company announced the completion of its £13 million pre-Series A financing round. The company is currently developing its KnotBody pipeline, including candidates with significant potential to be first-in-class and best-in-class therapeutics.
Contact
About Maxion Therapeutics
Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.
The Company is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody® technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using state-of-the-art phage and mammalian display technologies. Maxion was founded in 2020 by highly respected biotech entrepreneurs and scientists Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO. Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. Maxion’s portfolio and growth is being advanced by a team of highly experienced leaders in the discovery and development of antibody-based drugs. The Company is based near Cambridge, UK and is backed by international blue-chip investors.
For more information, please visit: https://www.maxiontherapeutics.com/
